Trials / Completed
CompletedNCT02739009
First in Human of Single and Multiple Doses of MOR106
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double-blind, placebo-controlled, dose-escalation, phase I study for the assessment of safety, tolerability and pharmacokinetics of single ascending doses of MOR106 in healthy male subjects and multiple ascending doses in subjects with moderate to severe atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MOR106 single ascending doses, intravenous | |
| DRUG | Placebo single ascending doses, intravenous | |
| DRUG | MOR106 multiple ascending doses, intravenous | |
| DRUG | Placebo multiple intravenous administrations |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2017-08-01
- Completion
- 2017-08-01
- First posted
- 2016-04-14
- Last updated
- 2017-10-05
Locations
4 sites across 4 countries: Belgium, Hungary, Moldova, Romania
Source: ClinicalTrials.gov record NCT02739009. Inclusion in this directory is not an endorsement.